AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19691714 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-training intervention
Number of subjects: 384
Study 19691714 — intervention group
Group type: COMPARATOR
Intervention: Control group (single workshop)
Number of subjects: 384
Study 19691714 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention rates
Number of subjects: 384
Study 17533492 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin
Number of subjects: 0
Study 17533492 — intervention group
Group type: COMPARATOR
Intervention: Oral tetracycline plus topical adapalene
Number of subjects: 0
Study 15013339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 37
Study 15013339 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 37
Study 11772906 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24
Study 11772906 — intervention group
Group type: COMPARATOR
Intervention: Continuous peritoneal insulin infusion (CPII)
Number of subjects: 24
Study 11772906 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII (using ELISA)
Number of subjects: 24
Study 11772906 — intervention group
Group type: COMPARATOR
Intervention: CPII (using ELISA)
Number of subjects: 24
Study 11772906 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of AIA formation between CSII and CPII
Number of subjects: 24
Study 9694103 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg every 24 hours
Number of subjects: 50
Study 9694103 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/kg every 8 hours
Number of subjects: 50
Study 8127332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5 percent)
Number of subjects: 41
Study 8127332 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone (5.7 mg)
Number of subjects: 41
Study 2771809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 8
Study 2771809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 8
Study 2771809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 356238 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/day proquazone
Number of subjects: 40
Study 356238 — intervention group
Group type: COMPARATOR
Intervention: 500 mg/day naproxen
Number of subjects: 40
Study 31864581 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic suprapectoral biceps tenodesis (ASPBT)
Number of subjects: 75
Study 31864581 — intervention group
Group type: COMPARATOR
Intervention: Open subpectoral biceps tenodesis (OSPBT)
Number of subjects: 75
Study 30756451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratacel® (novel silicone-based wound dressing)
Number of subjects: 20
Study 30756451 — intervention group
Group type: COMPARATOR
Intervention: Aquaphor® (standard of care)
Number of subjects: 20
Study 28961833 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/day)
Number of subjects: 483
Study 25874370 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 min)
Number of subjects: 41
Study 25874370 — intervention group
Group type: COMPARATOR
Intervention: Placebo stretching control
Number of subjects: 41
Study 23977072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 40
Study 23977072 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 22846542 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based brief personalized feedback intervention (n=476)
Number of subjects: 1380
Study 22846542 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based personalized brief advice intervention (n=450)
Number of subjects: 1380
Study 22846542 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group (n=454)
Number of subjects: 1380
Study 19416946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with oestradiol plus noretisterone acetate
Number of subjects: 88
Study 19416946 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 88
Study 19416946 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamin D3 and calcium supplementation without HRT)
Number of subjects: 88
Study 17350965 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster‐Stratton Incredible Years basic parenting programme
Number of subjects: 116
Study 17350965 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 116
Study 15226325 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m² plus Paclitaxel 175 mg/m² (AT)
Number of subjects: 275
Study 15226325 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m² plus Cyclophosphamide 600 mg/m² (AC)
Number of subjects: 275
Study 11432650 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient, subacute rehabilitation at home (n = 90)
Number of subjects: 180
Study 11432650 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient follow-up (n = 90)
Number of subjects: 180
Study 9555954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/day)
Number of subjects: 8
Study 7889227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric rank methods (e.g., Wilcoxon rank sum test, Wilcoxon signed rank test)
Number of subjects: 0
Study 7889227 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensions for crossover studies comparing more than two treatments
Number of subjects: 0
Study 3265921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 18
Study 3265921 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (Control)
Number of subjects: 18
Study 30231024 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV community delivery model
Number of subjects: 2172
Study 30231024 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (facility-based care)
Number of subjects: 2172
Study 28546013 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (Group C)
Number of subjects: 200
Study 28546013 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube assisted group (Group ET)
Number of subjects: 200
Study 28546013 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope group (Group MG)
Number of subjects: 200
Study 28546013 — intervention group
Group type: EXPERIMENTAL
Intervention: Head in the lateral position group (Group L)
Number of subjects: 200
Study 26469308 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance game training for 5 weeks
Number of subjects: 82
Study 26469308 — intervention group
Group type: COMPARATOR
Intervention: Control group recording levels of physical activity
Number of subjects: 82
Study 23751136 — intervention group
Group type: EXPERIMENTAL
Intervention: Added training and technical support in trial communities
Number of subjects: 8092
Study 23751136 — intervention group
Group type: COMPARATOR
Intervention: Regular prevention efforts supported by national alcohol and drug action plans in control communities
Number of subjects: 8092
Study 21596925 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4,000 mg/day)
Number of subjects: 36
Study 21596925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1,200 mg/day)
Number of subjects: 36
Study 21596925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18942491 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 39
Study 18942491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17220049 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% nipradilol, applied twice daily for 52 weeks
Number of subjects: 196
Study 17220049 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% nipradilol, applied twice daily for 8 weeks
Number of subjects: 196
Study 17220049 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol, applied twice daily for 8 weeks
Number of subjects: 196
Study 12692112 — intervention group
Group type: EXPERIMENTAL
Intervention: D19S246 locus; significant differences in allele and genotype distributions
Number of subjects: 239
Study 12692112 — intervention group
Group type: COMPARATOR
Intervention: Control group; 100 controls in initial screening and 63 controls in follow-up
Number of subjects: 239
Study 11124552 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliglecaprone 25 (Monocryl)
Number of subjects: 183
Study 11124552 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycomer 631 (Biosyn)
Number of subjects: 183
Study 8956759 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 in sera
Number of subjects: 19
Study 8956759 — intervention group
Group type: EXPERIMENTAL
Intervention: sVCAM‐1 in sera
Number of subjects: 19
Study 8956759 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble L‐selectin in sera
Number of subjects: 19
Study 8956759 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 in ELF
Number of subjects: 19
Study 8956759 — intervention group
Group type: EXPERIMENTAL
Intervention: sVCAM‐1, soluble E‐selectin, and soluble L‐selectin in ELF
Number of subjects: 19
Study 1372660 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized hyperthermia treatment (43 +/- 0.5C, 6 sessions)
Number of subjects: 68
Study 1372660 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (no radio frequency power applied)
Number of subjects: 68
Study 2951800 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (200 micrograms of fenoterol and 80 micrograms of ipratropium bromide)
Number of subjects: 16
Study 2951800 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol (1 mg)
Number of subjects: 16
Study 2951800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two puffs)
Number of subjects: 16
Study 30012361 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cTnI measurement
Number of subjects: 900
Study 30012361 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-72 hour cTnI measurement
Number of subjects: 900
Study 30012361 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 day cTnI measurement
Number of subjects: 900
Study 26342053 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% O2
Number of subjects: 147
Study 26342053 — intervention group
Group type: COMPARATOR
Intervention: 20% O2
Number of subjects: 147
Study 24895001 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (10 hours educational program, followed by on demand support by phone)
Number of subjects: 1018
Study 24895001 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 1018
Study 22704111 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism rs9810233
Number of subjects: 528
Study 22704111 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism rs1920201
Number of subjects: 528
Study 20553136 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 2% lidocaine with 1:100,000 epinephrine/sodium bicarbonate
Number of subjects: 0
Study 20553136 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 0
Study 18711169 — intervention group
Group type: EXPERIMENTAL
Intervention: PITX2 DNA methylation
Number of subjects: 399
Study 18711169 — intervention group
Group type: COMPARATOR
Intervention: Established prognostic factors (tumor size, grade, and age)
Number of subjects: 399
Study 16551364 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dimensional guided M-mode echo measurements
Number of subjects: 20
Study 14700373 — intervention group
Group type: EXPERIMENTAL
Intervention: Schematic scene condition
Number of subjects: 30
Study 14700373 — intervention group
Group type: COMPARATOR
Intervention: Taxonomic grid condition
Number of subjects: 30
Study 14700373 — intervention group
Group type: COMPARATOR
Intervention: Schematic grid condition
Number of subjects: 30
Study 10723150 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (cozaar, MSD, USA) 25 mg/day for 48 weeks
Number of subjects: 116
Study 10723150 — intervention group
Group type: COMPARATOR
Intervention: Basic medication with nitrates, diuretic (on demand), digoxin, and aspirin
Number of subjects: 116
Study 10155875 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care procedures (including screening tests)
Number of subjects: 0
Study 10155875 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 0
Study 10155875 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary midwifery service
Number of subjects: 0
Study 1330411 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced diet
Number of subjects: 9
Study 1330411 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein diet
Number of subjects: 9
Study 1330411 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate diet
Number of subjects: 9
Study 1330411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat diet
Number of subjects: 9
Study 1330411 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study 3970769 — intervention group
Group type: EXPERIMENTAL
Intervention: IAC-CPR
Number of subjects: 291
Study 3970769 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 291
Study 31348204 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic method using texture analysis software Mazda3.3
Number of subjects: 120
Study 31348204 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model
Number of subjects: 120
Study 31348204 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machine model
Number of subjects: 120
Study 31348204 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network model
Number of subjects: 120
Study 31348204 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups based on median of GCS score, NIHSS score, and maximum diameter of hematoma
Number of subjects: 120
Study 28574985 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation treatment (MRT)
Number of subjects: 122
Study 28574985 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 122
Study 25550339 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2-3 g/day
Number of subjects: 150
Study 25550339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) 0.06-0.1 mg/kg/day
Number of subjects: 150
Study 23670167 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabucco technique
Number of subjects: 162
Study 23670167 — intervention group
Group type: EXPERIMENTAL
Intervention: Valenti technique
Number of subjects: 162
Study 23670167 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 162
Study 23670167 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein, Trabucco, and Valenti techniques
Number of subjects: 162
Study 22331646 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed tomato product
Number of subjects: 25
Study 22331646 — intervention group
Group type: COMPARATOR
Intervention: Non-tomato alternative
Number of subjects: 25
Study 19289319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest (48 hours)
Number of subjects: 12
Study 19289319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory activity (48 hours)
Number of subjects: 12
Study 17618324 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (0.454% stabilized stannous fluoride/sodium hexametaphosphate)
Number of subjects: 0
Study 17618324 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (negative control)
Number of subjects: 0
Study 15229333 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy BMI
Number of subjects: 439
Study 15229333 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI of 28
Number of subjects: 439
Study 15229333 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI of 36
Number of subjects: 439
Study 11529904 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 26
Study 11529904 — intervention group
Group type: COMPARATOR
Intervention: Allergen challenge
Number of subjects: 26
Study 9736592 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity warfarin (INR, 2.0 to 2.5) plus aspirin
Number of subjects: 506
Study 9736592 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR, 1.5) plus aspirin
Number of subjects: 506
Study 9736592 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 506
Study 7520497 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist treatment for three to six months
Number of subjects: 17
Study 7520497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17
Study 3278190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 10
Study 3278190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 10
Study 3278190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30447688 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of mental healthcare in participants with poor MH (9% of participants) who did not receive mental healthcare at baseline.
Number of subjects: 5970
Study 30447688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of mental healthcare in participants with good MH (66% of participants) who received mental healthcare at baseline.
Number of subjects: 5970
Study 30447688 — intervention group
Group type: COMPARATOR
Intervention: Odds ratio for initiation of mental healthcare based on MH screening status.
Number of subjects: 5970
Study 30447688 — intervention group
Group type: COMPARATOR
Intervention: Odds ratio for cessation of mental healthcare based on MH screening status.
Number of subjects: 5970
Study 28468620 — intervention group
Group type: EXPERIMENTAL
Intervention: VB-001
Number of subjects: 168
Study 28468620 — intervention group
Group type: COMPARATOR
Intervention: ZPTO shampoo
Number of subjects: 168
Study 26272452 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2 % + methylprednisolone 1 mg/kg
Number of subjects: 120
Study 26272452 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine + steroid
Number of subjects: 120
Study 26272452 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.2 % or placebo
Number of subjects: 120
Study 23735723 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitization (IS) therapy
Number of subjects: 1479
Study 23735723 — intervention group
Group type: COMPARATOR
Intervention: Insulin-providing (IP) therapy
Number of subjects: 1479
Study 21168231 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Body Control (ABC) Program
Number of subjects: 70
Study 21168231 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 70
Study 19404608 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum 500 microg
Number of subjects: 47
Study 19404608 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum 4 microg
Number of subjects: 47
Study 19404608 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum 20 microg
Number of subjects: 47
Study 19404608 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum 100 microg
Number of subjects: 47
Study 19404608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 16509763 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release glipizide 5mg (Glynase)
Number of subjects: 0
Study 16509763 — intervention group
Group type: COMPARATOR
Intervention: Extended-release glipizide 5mg (Glynase) XL
Number of subjects: 0
Study 16509763 — intervention group
Group type: COMPARATOR
Intervention: Glucotrol XL
Number of subjects: 0
Study 16509763 — intervention group
Group type: COMPARATOR
Intervention: New formulation developed in the laboratory (GLPF)
Number of subjects: 0
Study 16509763 — intervention group
Group type: COMPARATOR
Intervention: Extended-release glipizide formulations
Number of subjects: 0
Study 15366326 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulfate 2.2 mg
Number of subjects: 20
Study 15366326 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulfate 4.4 mg
Number of subjects: 20
Study 15366326 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulfate 8.8 mg
Number of subjects: 20
Study 15366326 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulfate 17.6 mg
Number of subjects: 20
Study 15366326 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 20
Study 10904511 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, 500 mg twice daily (n = 14)
Number of subjects: 26
Study 10904511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 26
Study 9290985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 10
Study 8363025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic intubation (group 1)
Number of subjects: 30
Study 8363025 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with topical anaesthesia (group 2)
Number of subjects: 30
Study 8363025 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscopy without topical anaesthesia (group 3)
Number of subjects: 30
Study 3521259 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 99
Study 3521259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 31780337 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscapularis tenotomy
Number of subjects: 100
Study 31780337 — intervention group
Group type: COMPARATOR
Intervention: Subscapularis peel
Number of subjects: 100
Study 31140192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rome IV criteria for functional constipation
Number of subjects: 951
Study 31140192 — intervention group
Group type: COMPARATOR
Intervention: Rome III criteria for functional constipation
Number of subjects: 951
Study 28522130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1,600 IU and calcium carbonate 1,000 mg
Number of subjects: 150
Study 28522130 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate alone
Number of subjects: 150
Study 26094330 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with inflammatory bowel diseases
Number of subjects: 16
Study 26094330 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons), N=13
Number of subjects: 16